Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;58(7):1311-7.
doi: 10.1111/j.1532-5415.2010.02906.x. Epub 2010 Jun 1.

Age-varying association between statin use and incident Alzheimer's disease

Ge Li  1 , Jane B Shofer, Isaac C Rhew, Walter A Kukull, Elaine R Peskind, Wayne McCormick, James D Bowen, Gerard D Schellenberg, Paul K Crane, John C S Breitner, Eric B Larson
Affiliations

Age-varying association between statin use and incident Alzheimer's disease

Ge Li et al. J Am Geriatr Soc. 2010 Jul.

Abstract

Objectives: To determine whether risk reduction of statins for Alzheimer's disease (AD) varies by age or presence of apolipoprotein E (APOE) epsilon4 allele.

Design: A cohort of cognitively intact elderly participants was assessed biennially for dementia and AD.

Setting: Community based.

Participants: Three thousand three hundred ninety-two members of a health maintenance organization (HMO) aged 65 and older and without dementia.

Measurements: Statin use was identified from the HMO pharmacy database, and proportional hazards models were applied with statin use as a time-dependent covariate to assess the association between statins and AD and the modifying effects of age and the APOE epsilon4 allele.

Results: Over an average of 6.1 years of follow-up of 3,099 participants, 263 participants developed probable AD. The adjusted hazard ratio (aHR) for statin use was 0.62 (95% confidence interval (CI)=0.40-0.97) for AD in models including demographic characteristics and vascular risk factors as covariates. The strength of the association between statins and AD diminished with age (statin-by-age at entry interaction P=.04); the aHR in those younger than 80 was 0.44 (95% CI=0.25-0.78), versus 1.22 (95% CI=0.61-2.42) for aged 80 and older. The interaction term for statin use-by-APOE epsilon4 was not significant (P=.65).

Conclusion: This enlarged study confirms earlier findings that statin therapy in early old age, but not in late age, may be associated with a lower risk of AD. The relationship between statin use and AD was consistent across APOE genotypes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper.

Figures

Figure 1
Figure 1
Adjusted HR and 95% confidence interval of statin therapy for AD by age-at-entry based on Cox models adjusted for cohort, gender, race, years of education, CASI score at baseline, comorbid vascular diseases, BMI, history of cigarette smoking and other LLA use. HR: hazard ration; AD: Alzheimer’s disease; CASI: Cognitive Abilities Screening Instrument (score range 0 – 100); BMI: body mass index; LLA: other lipid lowering agent.
Figure 2
Figure 2
Adjusted HR and 95% confidence interval of statin therapy for AD by age-at-entry and APOE allele ε2/ε2 or ε2/ε3 (circle), ε3/ε3 (triangle) and ε2/ε4, ε3/ε4, or ε4/ε4 ('x') based on stratified Cox models adjusted for cohort, gender, race, years of education, CASI score at baseline, comorbid vascular diseases, BMI, history of cigarette smoking and other LLA use, with strata defined by 5 category age. HR: hazard ration; AD: Alzheimer’s disease; CASI: Cognitive Abilities Screening Instrument (score range 0 – 100); BMI: body mass index; LLA: other lipid lowering agent.
See this image and copyright information in PMC

Comment in

References

    1. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ. 2001;322:1447–1451. - PMC - PubMed
    1. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study. Neurology. 2004;63:1624–1628. - PubMed
    1. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223–227. - PubMed
    1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923. - PubMed
    1. Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian simvastatin survival study. Circulation. 2000;101:1366–1371. - PubMed

Publication types

Substances